IV Haloperidol for the Treatment of Headache in the ED
- Registration Number
- NCT02747511
- Lead Sponsor
- Western Michigan University School of Medicine
- Brief Summary
Single center, double-blind, randomized, placebo-controlled trial evaluating analog pain scores in patients who present to the emergency department (ED) with a complaint of headache. A total of 150 patients age 13-55 presenting to the emergency department with headache will be enrolled from October 2015 - October 2016. Patients will be randomized and pain scores and side effects will be recorded at 0, 30, 60, and 90 minutes. Follow-up will be performed by telephone at 24 hours.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 118
Inclusion Criteria
- Emergency Department patients that complain of headache or migraine
- Males and females age 13-55
- English is primary language
Exclusion Criteria
- Abnormal blood pressure (>200/100)
- Sudden rapid onsent (normal to worst pain in minutes)
- Fever
- Trauma
- Any history of masses, strokes, head injury or other causes of abnormal anatomy
- QT greater than 450 ms on EKG
- Allergy to Haldon
- Any altered mental status (GCS <15)
- Pregnancy
- Any abnormalities on neurologic exam
- Any clinician concern that would require CT scan of brain
- Any prisoner or ward of state
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Haloperidol Haloperidol -
- Primary Outcome Measures
Name Time Method >50% reduction in pain per Visual Analog Scale (VAS) 90 minute interval
- Secondary Outcome Measures
Name Time Method